A347850 Stock Overview

A clinical-stage biotech company, develops medicines in South Korea and the United States. More details

A347850 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings have grown 10.8% per year over the past 5 years

Risk Analysis

Volatile share price over the past 3 months compared to the KR market

My Notes

Capture your thoughts, links and company narrative

D&D Pharmatech Inc. Competitors

OliX Pharmaceuticals

KOSDAQ:A226950

₩284.3b

EuBiologics

KOSDAQ:A206650

₩433.7b

L&C BIOLTD

KOSDAQ:A290650

₩488.9b

BNC Korea

KOSDAQ:A256840

₩266.8b

Price History & Performance

Summary of share price highs, lows and changes for D&D Pharmatech
Historical stock prices
Current Share Price	₩47,000.00
52 Week High	₩53,900.00
52 Week Low	₩25,100.00
Beta	0
1 Month Change	42.21%
3 Month Change	17.21%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	28.77%

Recent updates

Shareholder Returns

	A347850	KR Biotechs	KR Market
7D	-0.7%	-3.9%	-3.7%
1Y	n/a	15.6%	-10.4%

Return vs Industry: Insufficient data to determine how A347850 performed against the KR Biotechs industry.

Return vs Market: Insufficient data to determine how A347850 performed against the KR Market.

Price Volatility

Is A347850's price volatile compared to industry and market?
A347850 volatility
A347850 Average Weekly Movement	11.9%
Biotechs Industry Average Movement	8.7%
Market Average Movement	6.6%
10% most volatile stocks in KR Market	12.7%
10% least volatile stocks in KR Market	3.3%

Stable Share Price: A347850's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A347850's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

Founded	Employees	CEO	Website
2014	n/a	Seul-ki Lee	www.ddpharmatech.com

D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson’s disease (PD), Alzheimer’s disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical trials to treat NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03 that is in Phase I clinical trials for the treatment of PD, AD, and neuroinflammation; PMI04, which is in Phase I clinical trials to treat PD, AD, ALS, and depression; and PMI05 and PMI06 that are in Phase I clinical trials for the treatment of oncology and immuno-oncology.

D&D Pharmatech Inc. Fundamentals Summary

How do D&D Pharmatech's earnings and revenue compare to its market cap?
A347850 fundamental statistics
Market cap	₩495.51b
Earnings (TTM)	-₩18.72b
Revenue (TTM)	₩8.19b

60.5x

P/S Ratio

-26.5x

P/E Ratio

Is A347850 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A347850 income statement (TTM)
Revenue	₩8.19b
Cost of Revenue	₩16.66m
Gross Profit	₩8.17b
Other Expenses	₩26.89b
Earnings	-₩18.72b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.78k
Gross Margin	99.80%
Net Profit Margin	-228.63%
Debt/Equity Ratio	2.2%

How did A347850 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 06:09
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

D&D Pharmatech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

D&D Pharmatech KOSDAQ:A347850 Stock Report